Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "Ibrutinib"

Human medicines European public assessment report (EPAR): Im...

This is a summary of the European public assessment report (EPAR) for Imbruvica. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ... European Medicines Agency, 3 days ago

4 images for Ibrutinib

Pharmaceutical Journal, 2 days ago
OncLive, 1 month ago
OncLive, 1 month ago
British Journal of Haematology, 1 month ago

IMBRUVICA (ibrutinib) ya está aprobado en Europa para el tratamiento de dos cánceres sanguíneos

SCHAFFHAUSEN, Suiza, 20 de octubre de 2014 /PRNewswire/ --Pharmacyclics Switzerland GmbH, una filial de Pharmacyclics, Inc. (NASDAQ: PCYC ), ha anunciado hoy que la Comisión Europea (CE) ha concedido una autorización de marketing para IMBRUVICA ...
 PR Newswire1 month ago
Bioresearch Online

IMBRUVICA ibrutinib Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia

By a News Reporter-Staff News Editor at Biotech Week Janssen Research & Development, LLC ("Janssen") announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA() (ibrutinib) to the U.S. Food and Drug Administration (FDA) by ...
 Pharmacy Choice3 weeks ago AstraZeneca And Pharmacyclics Enter Immuno-Oncology Clinical Trial Collaboration With IMBRUVICA® In Solid Tumors  ADVFN UK3 weeks ago PHARMACYCLICS : IMBRUVICA® ibrutinib Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia  4 Traders1 month ago IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia  Stock Nod1 month ago
[x]  
Securities Technology Monitor

IMBRUVICA® (ibrutinib) Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology (ASH) Annual Meeting

News Story Sorry, the story you were looking for is not available. Back to News Tweet Radar -ALLSYMB- AIG GOOG Scroll over any stock symbol to predict whether that stock's value will go up or down and to view other valuable ...
 PredictWallStreet3 weeks ago TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting  Morningstar.com3 weeks ago IMBRUVICA (ibrutinib) Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology (ASH) Annual Meeting  Pharmacy Choice3 weeks ago IMBRUVICA?? (ibrutinib) Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology (ASH) Annual Meeting  Presentation Master3 weeks ago
[x]  

Health Canada approves IMBRUVICA for chronic lymphocytic leukemia

Janssen Inc. has announced Health Canada has approved IMBRUVICA (ibrutinib) for the treatment of the blood cancer chronic lymphocytic leukemia (CLL). It is indicated for the treatment of patients with CLL, including those with 17p deletion, who have ...
 Medical News Today1 week ago European Commission approves ibrutinib in two forms of blood cancer  Ecancer Medicalscience1 month ago Health Canada Approves IMBRUVICA by Priority Review, Giving Physicians and Patients a Much-Needed Option in the Fight Against Chronic Lymphocytic Leukemia  Canada NewsWire1 week ago Health Canada Approves IMBRUVICA(TM) by Priority Review, Giving Physicians and Patients a Much-Needed Option in the Fight Against Chronic Lymphocytic Leukemia  Canada NewsWire1 week ago
[x]  

New Chronic Lymphocytic Leukemia Findings Has Been Reported by Investigators at Pharmacyclics Inc. (Ibrutinib inhibits BCR and NF-kappa B signaling...

New Chronic Lymphocytic Leukemia Findings Has Been Reported by Investigators at Pharmacyclics Inc. (Ibrutinib inhibits BCR and NF-kappa B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL) By a News ...
 4 Traders1 month ago Data from Pharmacyclics Inc. Advance Knowledge in Chronic Lymphocytic Leukemia (Kinetics of CLL cells in tissues and blood during therapy with the...  4 Traders1 month ago

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018 for the $5.4 Billion Market

Research and Markets (http://www.researchandmarkets.com/research/fpb3fv/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018" report to their offering.
 Individual.com14 hours ago Research and Markets: OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018 for the $5.4 Billion Market  Green Technology8 hours ago RESEARCH AND MARKETS : OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018 for the $5.4 Billion Market  4 Traders12 hours ago
[x]  

Plymouth professor awarded grant to find effective treatment for patients with mantle cell lymphoma

Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer Research UK to carry out a ...
 News-Medical.Net1 day ago Funding to investigate an alternative to chemotherapy  EurekAlert!2 days ago

European Commission Approves IMBRUVICA(TM) in Two Forms of Blood Cancer

/PRNewswire/ -- First-in-class BTK inhibitor for complex orphan diseases CLL and MCL Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA(TM) (ibrutinib) capsules, a first-in-class, ...
 Individual.com2 days ago

Market Update: Bristol-Myers Squibb Company (NYSE:BMY) Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immun

[GlobeNewswire] NEW YORK and SOUTH SAN FRANCISCO, Calif. — Bristol-Myers Squibb Company and Five Prime Therapeutics, Inc. today announced that they have entered into an exclusive clinical collaboration agreement to evaluate … . . . → Read ...
 Industrial Info Financials4 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less